Biomarin Pharmaceutical Short Long Term Debt Total Over Time

BMRN Stock  USD 68.25  0.48  0.70%   
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Biomarin Pharmaceutical Performance and Biomarin Pharmaceutical Correlation.
To learn how to invest in Biomarin Stock, please use our How to Invest in Biomarin Pharmaceutical guide.
  
As of the 23rd of February 2025, Short and Long Term Debt Total is likely to grow to about 1.3 B.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Biomarin Pharmaceutical. If investors know Biomarin will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Biomarin Pharmaceutical listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
6.393
Earnings Share
2.21
Revenue Per Share
15.018
Quarterly Revenue Growth
0.156
Return On Assets
0.0515
The market value of Biomarin Pharmaceutical is measured differently than its book value, which is the value of Biomarin that is recorded on the company's balance sheet. Investors also form their own opinion of Biomarin Pharmaceutical's value that differs from its market value or its book value, called intrinsic value, which is Biomarin Pharmaceutical's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Biomarin Pharmaceutical's market value can be influenced by many factors that don't directly affect Biomarin Pharmaceutical's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Biomarin Pharmaceutical's value and its price as these two are different measures arrived at by different means. Investors typically determine if Biomarin Pharmaceutical is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Biomarin Pharmaceutical's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Specify up to 10 symbols:

Cross Equities Short Long Term Debt Total Analysis

Compare Biomarin Pharmaceutical and related stocks such as Seagen Inc, Alnylam Pharmaceuticals, and Exelixis Short Long Term Debt Total Over Time
Select Fundamental
Price To Sales RatioDividend Yield
Ptb RatioFree Cash Flow Yield
Operating Cash Flow Per ShareStock Based Compensation To Revenue
Capex To DepreciationPb Ratio
Free Cash Flow Per ShareRoic
Inventory TurnoverNet Income Per Share
Payables TurnoverSales General And Administrative To Revenue
Research And Ddevelopement To RevenueCapex To Revenue
PocfratioInterest Coverage
Payout RatioCapex To Operating Cash Flow
Pfcf RatioIncome Quality
RoePe Ratio
Return On Tangible AssetsEarnings Yield
Intangibles To Total AssetsCurrent Ratio
Receivables TurnoverDebt To Equity
Capex Per ShareRevenue Per Share
Debt To AssetsDays Sales Outstanding
Book Value Per ShareInvested Capital
Average PayablesEv To Sales
Days Of Inventory On HandAverage Inventory
Cash Per ShareDays Payables Outstanding
Net Current Asset ValueTangible Asset Value
Ev To Operating Cash FlowEv To Free Cash Flow
Net Debt To E B I T D ATangible Book Value Per Share
Graham NumberShareholders Equity Per Share
Graham Net NetAverage Receivables
Interest Debt Per ShareEnterprise Value Over E B I T D A
Short Term Coverage RatiosPrice Earnings Ratio
Price Book Value RatioPrice Earnings To Growth Ratio
Dividend Payout RatioPrice To Operating Cash Flows Ratio
Price To Free Cash Flows RatioPretax Profit Margin
Ebt Per EbitOperating Profit Margin
Effective Tax RateCompany Equity Multiplier
Long Term Debt To CapitalizationTotal Debt To Capitalization
Return On Capital EmployedDebt Equity Ratio
Ebit Per RevenueQuick Ratio
Dividend Paid And Capex Coverage RatioNet Income Per E B T
Cash RatioOperating Cash Flow Sales Ratio
Free Cash Flow Operating Cash Flow RatioCash Flow Coverage Ratios
Price To Book RatioFixed Asset Turnover
Capital Expenditure Coverage RatioPrice Cash Flow Ratio
Debt RatioCash Flow To Debt Ratio
Price Sales RatioReturn On Assets
Asset TurnoverNet Profit Margin
Gross Profit MarginPrice Fair Value
Return On EquityOperating Cycle
Days Of Payables OutstandingCash Conversion Cycle
Days Of Inventory OutstandingDays Of Sales Outstanding
Enterprise Value Multiple
2010201120122013201420152016201720182019202020212022202320242025
ALNY1.9 M161.5 M161.5 M161.5 M161.5 M161.5 M161.5 M41 M92.9 M303.8 M521.2 M997.6 M1.3 B2.7 B1.3 B1.4 B
EXEL13.3 M181.5 M335.7 M347.2 M361.7 M799.4 M189.1 M72 M56.9 M50.7 M49.1 M51.3 M190.2 M189.9 M190.8 M180.8 M
HALO400 K31.1 M31.1 M49.8 M49.9 M49.8 M216.6 M202.4 M126.4 M402.6 M397.2 M876.7 M1.5 B1.5 B1.5 B1.6 B
ARWRM2.3 M2.3 MM758.3 K2.7 M2.5 M2.3 M21.1 M21.1 M25.5 M81.6 M115.2 M510.6 M587.1 M616.5 M
INCY800 K614.3 M331.1 M661.6 M689.1 M619.9 M651.5 M24 M36.1 M60.2 M34.9 M34.3 M44.6 M38.3 M38 M36.1 M
IONS1.2 M218.8 M226.8 M232.6 M457.8 M406.6 M501.8 M594.5 M641.8 M772 M808.9 M1.2 B1.3 B1.5 B1.4 B1.5 B
APLS52.8 M52.8 M52.8 M52.8 M52.8 M52.8 M52.8 M52.8 M27 M157 M377.7 M210.2 M112.7 M110.9 M127.6 M164.8 M
PCVX3.9 M3.9 M3.9 M3.9 M3.9 M3.9 M3.9 M3.9 M3.9 M611 K16.8 M16.8 M17.9 M29.2 M33.6 M35.3 M
LQDA8.7 M8.7 M8.7 M8.7 M8.7 M8.7 M8.7 M23.5 M12.8 M24.4 M17.1 M16.1 M24.5 M3.5 M3.2 MM
LEGN269 K269 K269 K269 K269 K269 K269 K269 K4.3 M6.1 M3.4 M123 M284.5 M328.7 M378 M396.9 M
TECH600 K12.9 M12.9 M12.9 M116 M133.8 M349.9 M347.9 M505.2 M433.5 M420.6 M326 M455 M419.5 M482.5 M506.6 M
MREO2.8 M2.8 M2.8 M2.8 M2.8 M2.8 M3.1 M20.8 M21.5 M32.4 M17.9 M16.8 M12.8 MM6.8 M6.5 M
BPMC2.9 M2.9 M2.9 M2.9 MM7.9 M4.6 M16.3 M14.6 M95.9 M89.6 M111.4 M562.7 M774.1 M126.1 M166.4 M
AGIO113.7 M113.7 M113.7 M113.7 M113.7 M113.7 M113.7 M113.7 M113.7 M113.7 M105.2 M97.1 M85.7 M72 M57 M70.7 M
DAWN402 K402 K402 K402 K402 K402 K402 K402 K402 K402 K402 K220 K813 K408 K469.2 K506.8 K
JavaScript chart by amCharts 3.21.15Macroaxis Charts201220142016201820202022202410M1B
JavaScript chart by amCharts 3.21.15Alnylam Pharmaceuticalstotal: 9.6BExelixistotal: 3.3BHalozyme Therapeuticstotal: 8.5BArrowhead Pharmaceuticalstotal: 2BIncytetotal: 3.9BIonis Pharmaceuticalstotal: 11.8BApellis Pharmaceuticalstotal: 1.7BVaxcytetotal: 185.7MLiquidia Technologiestotal: 188.8MLegend Biotech Corptotal: 1.5BBio Techne Corptotal: 4.5BMereo BioPharma Grouptotal: 161.3MBlueprint Medicines Corptotal: 2BAgios Pharmtotal: 1.6BDay One Biopharmaceuticalstotal: 6.8M

Biomarin Pharmaceutical and related stocks such as Seagen Inc, Alnylam Pharmaceuticals, and Exelixis Short Long Term Debt Total description

My Equities

My Current Equities and Potential Positions

Biomarin Pharmaceutical
BMRN
Specialization
Health Care, Pharmaceuticals, Biotechnology & Life Sciences
LocationCalifornia; U.S.A
ExchangeNASDAQ Exchange
USD 64.91
100%
When determining whether Biomarin Pharmaceutical offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Biomarin Pharmaceutical's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biomarin Pharmaceutical Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biomarin Pharmaceutical Stock:
Biomarin Pharmaceutical technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.
A focus of Biomarin Pharmaceutical technical analysis is to determine if market prices reflect all relevant information impacting that market. A technical analyst looks at the history of Biomarin Pharmaceutical trading pattern rather than external drivers such as economic, fundamental, or social events. It is believed that price action tends to repeat itself due to investors' collective, patterned behavior. Hence technical analysis focuses on identifiable price trends and conditions. More Info...